Malaria vaccine provided protection 18 months after vaccination

  • July 29, 2014

The malaria vaccine RTS,S/AS01 was more effective among children than infants, but it had modest levels of efficacy overall and prevented a significant amount of clinical and severe malaria cases, according to results from an ongoing trial published in PLOS Medicine.

The RTS,S Clinical Trials Partnership randomly assigned 6,537 infants, aged 6 to 12 weeks, and 8,923 children, aged 5 to 17 months, to three doses of RTS,S/AS01 (Mosquirix, GlaxoSmithKline) or a comparator vaccine. Researchers conducted an 18-month follow-up. Study participants who received a comparator vaccine served as the control and were administered VeroRab (Sanofi-Pasteur) or Menjugate (Novartis). The study was conducted from March 2009 to January 2011 across 11 sites in seven African countries.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »